GLUE EBITDA Margin
Monte Rosa Therapeutics Inc · EBITDA Margin
GLUE EBITDA Margin
Latest reported-542.51%period ending
GLUE TTM EBITDA Margin (-12231.77% → -542.51%)
TTM ebitda margin
High-resolution chart · PNG
GLUE ebitda margin history
Trailing twelve months (TTM). Each value covers four complete reported quarters.
| Period ending | EBITDA Margin |
|---|---|
| -542.514% | |
| -287.626% | |
| -25.3631% | |
| 16.6814% | |
| 20.6539% | |
| 11.1194% | |
| -81.9986% | |
| -741.8965% | |
| -2,162.6498% | |
| -12,231.7669% |